Answers are grounded in this paper and cite their sources.
Purpose: Increasing age is the strongest risk factor in developing AMD. Growing evidence suggests that systemic immunosenescence is implicated in its pathogenesis. This study aims to characterize age-related T-cell differentiation in late-stage AMD by comparing patients with geographic atrophy (GA) and neovascular AMD (nAMD) to a shared healthy control group. Methods: Patients with GA or nAMD were recruited from an outpatient AMD-clinic. Individuals with immunological disease, cancer or use of immune-modulating medication were excluded. Blood samples from all participants were stained with monoclonal antibodies and analyzed with flow cytometry to assess T-cell subsets (naive, central memory [CM], effector memory [EM], and effector memory with CD45ra+ [EMRA]) and expression of the age-associated costimulatory markers (CD27, CD28, and CD56). Results: One hundred twenty-eight patients were included in this study. Patients with GA demonstrated significantly higher levels of CD8+CD28-EM T cells (P = 0.038) and significantly lower levels of CD4+CD56+CM T cells (P = 0.021) compared with healthy controls. Patients with nAMD showed significantly higher levels of naive CD4+CD56+ and CD4+CD56+CM T cells (P = 0.008 and P = 0.008) compared to patients with GA. Conclusions: Patients with GA demonstrated an increased proportion of CD8+CD28- EM T cells, a finding similar to other infectious, autoimmune, and neurodegenerative disorders. The increased expression of CD56+ T cells in patients with nAMD supports CD56 having a potential role in angiogenic regulation. Contrarily, we suggest the reduced CD56 expression in patients with GA might contribute to GA pathogenesis.
Loading...
Hartelius et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: